SCHEMBL4790440

SCHEMBL4790440

CC(=O)NCC(C)c1ccc2nc(Oc3ccc(N)cc3)sc2c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACACB O00763 6/20 0.41
NPC1 O15118 4/20 0.41
RAB9A P51151 4/20 0.41
LTA4H P09960 2/20 0.40
KCNH2 Q12809 2/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
SCN4A P35499 1/20 0.40
SCD O00767 1/20 0.40
ALOX5 P09917 2/20 0.40
CYP1A2 P05177 2/20 0.38
CYP3A4 P08684 2/20 0.38
CYP2C19 P33261 2/20 0.38
CYP2D6 P10635 1/20 0.38
CA2 P00918 1/20 0.38
HTT P42858 1/20 0.38
DYRK1A Q13627 1/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
ALDH1A1 P00352 2/20 0.38
LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4519215 0.90 ACACB (0.47) ACACBNPC1RAB9AHTTMEN1
SCHEMBL4519186 0.90 NPC1 (0.52) ACACBNPC1RAB9ALTA4HKCNH2
SCHEMBL4516183 0.89 ACACB (0.46) ACACBNPC1RAB9AHTTMEN1
SCHEMBL4520509 0.87 NPC1 (0.44) ACACBNPC1RAB9ALTA4HKCNH2
SCHEMBL4514304 0.87 NPC1 (0.47) NPC1RAB9ASMN1; SMN2CYP1A2CYP3A4
SCHEMBL4511372 0.86 NPC1 (0.44) NPC1RAB9ALTA4HKCNH2SMN1; SMN2
SCHEMBL4525186 0.86 NPC1 (0.50) ACACBNPC1RAB9ALTA4HKCNH2
SCHEMBL4521582 0.85 NPC1 (0.45) NPC1RAB9ASMN1; SMN2CYP1A2CYP3A4
SCHEMBL2622434 0.84 ACACB (0.43) ACACBNPC1RAB9AEPHX2
SCHEMBL4508992 0.84 NPC1 (0.41) NPC1RAB9ALTA4HKCNH2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1996567-A2 NOVEL ACETYL-COA CARBOXYLASE (ACC) INHIBITORS AND THEIR USE IN DIABETES, OBESITY AND METABOLIC SYNDROME ABBOTT LABORATORIES (US) 2008-12-03 EP disclosed
WO-2007095601-A2 NOVEL ACETYL-COA CARBOXYLASE (ACC) INHIBITORS AND THEIR USE IN DIABETES, OBESITY AND METABOLIC SYNDROME ABBOTT LABORATORIES (US) 2007-08-23 WO disclosed